Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.
2.

Immunization strategies for the prevention of pneumovirus infections.

Bennett N, Ellis J, Bonville C, Rosenberg H, Domachowske J.

Expert Rev Vaccines. 2007 Apr;6(2):169-82. Review.

PMID:
17408367
3.

The pneumonia virus of mice infection model for severe respiratory syncytial virus infection: identifying novel targets for therapeutic intervention.

Rosenberg HF, Bonville CA, Easton AJ, Domachowske JB.

Pharmacol Ther. 2005 Jan;105(1):1-6. Review.

PMID:
15626452
4.

Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment.

Boukhvalova MS, Yim KC, Kuhn KH, Hemming JP, Prince GA, Porter DD, Blanco JC.

J Infect Dis. 2007 Feb 15;195(4):511-8.

5.

The Pneumonia Virus of Mice (PVM) model of acute respiratory infection.

Dyer KD, Garcia-Crespo KE, Glineur S, Domachowske JB, Rosenberg HF.

Viruses. 2012 Dec;4(12):3494-510. Review.

6.

Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium.

Villenave R, Broadbent L, Douglas I, Lyons JD, Coyle PV, Teng MN, Tripp RA, Heaney LG, Shields MD, Power UF.

J Virol. 2015 Dec;89(24):12309-18. doi: 10.1128/JVI.02119-15.

7.

Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.

Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, Guarino B, Silacci C, Marcandalli J, Marsland BJ, Piralla A, Percivalle E, Sallusto F, Baldanti F, Lanzavecchia A.

Nature. 2013 Sep 19;501(7467):439-43. doi: 10.1038/nature12442.

PMID:
23955151
8.

Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.

Groothuis JR, Hoopes JM, Hemming VG.

Adv Ther. 2011 Feb;28(2):110-25. doi: 10.1007/s12325-010-0101-y. Review.

PMID:
21318605
9.

Respiratory syncytial virus infections: recent prospects for control.

Sidwell RW, Barnard DL.

Antiviral Res. 2006 Sep;71(2-3):379-90. Review.

PMID:
16806515
10.

New strategies for control of respiratory syncytial virus infection.

Nokes JD, Cane PA.

Curr Opin Infect Dis. 2008 Dec;21(6):639-43. doi: 10.1097/QCO.0b013e3283184245. Review.

PMID:
18978532
11.

Respiratory syncytial virus infection in adults.

Falsey AR.

Semin Respir Crit Care Med. 2007 Apr;28(2):171-81. Review.

PMID:
17458771
12.

Activation and inactivation of antiviral CD8 T cell responses during murine pneumovirus infection.

Claassen EA, van der Kant PA, Rychnavska ZS, van Bleek GM, Easton AJ, van der Most RG.

J Immunol. 2005 Nov 15;175(10):6597-604.

13.

Animal models of human respiratory syncytial virus disease.

Bem RA, Domachowske JB, Rosenberg HF.

Am J Physiol Lung Cell Mol Physiol. 2011 Aug;301(2):L148-56. doi: 10.1152/ajplung.00065.2011. Review.

14.

Pathogen recognition receptor crosstalk in respiratory syncytial virus sensing: a host and cell type perspective.

Marr N, Turvey SE, Grandvaux N.

Trends Microbiol. 2013 Nov;21(11):568-74. doi: 10.1016/j.tim.2013.08.006.

15.

Respiratory syncytial virus disease: update on treatment and prevention.

Krilov LR.

Expert Rev Anti Infect Ther. 2011 Jan;9(1):27-32. doi: 10.1586/eri.10.140. Review.

PMID:
21171875
16.

The distinguishing features of human metapneumovirus and respiratory syncytial virus.

Papenburg J, Boivin G.

Rev Med Virol. 2010 Jul;20(4):245-60. doi: 10.1002/rmv.651. Review.

PMID:
20586081
17.

Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.

Feltes TF, Sondheimer HM.

Expert Opin Biol Ther. 2007 Sep;7(9):1471-80. Review.

PMID:
17727335
19.

Pathogenesis of respiratory syncytial virus infection.

Tripp RA.

Viral Immunol. 2004;17(2):165-81. Review.

PMID:
15279697
Items per page

Supplemental Content

Support Center